Expanded access, also known as compassionate use, refers to the use of an investigational drug outside of a clinical trial for patients with serious or life-threatening conditions who have exhausted treatment options and are unable to participate in a clinical trial.
Repertoire Immune Medicines is committed to developing new therapies through well-designed clinical trials and regulatory review, which we believe is the most appropriate way to evaluate safety and efficacy and make new treatments available to patients as quickly and responsibly as possible. Information about Repertoire’s clinical trial of RPTR-1-201 is available at www.clinicaltrials.gov under NCT07293754.
At this time, Repertoire does not offer expanded access or compassionate use for RPTR-1-201. Expanded access may be considered in the future only after sufficient safety and efficacy information has been obtained through clinical trials.
For additional information regarding the status of our investigational drugs, please contact Repertoire Immune Medicines at eap@repertoire.com.